News

Scripps Research scientists found that a “one-two punch” of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, including Hodgkin lymphoma.

Jin is named a 2024 Pew Scholar and receives the McKnight Scholar Award, supporting her research in mapping the genes and cell types in brain development.

Scripps Research’s vision to translate basic scientific discovery into effective treatments that benefit human health strikes a chord with Barbara Kosacz, JD—making her addition to the institution’s Board of Directors fitting.

Skaggs family also honored at commencement ceremony as first recipients of Scripps Research Presidential Medal

By recording detailed electrical and protein measurements of individual brain cells, researchers revealed new potential drug targets for the neurodegenerative disease.

Scripps Research scientists have developed a potential drug-like molecule that blocks the first stage of type A influenza infection.

Scripps Research scientists develop CRISPR screen technology to determine disease mechanism from tissues with accelerated speed.

C-H activation-based method should speed drug molecule design and diversification.

Blackmond’s wide-ranging work has shaped origin of life theories, our understanding of complex organic reaction mechanisms, drug development and much more.

Johnson’s multi-disciplinary research has been instrumental in shaping our modern understanding of viruses.

New list honors 100 individuals who most influenced global health in 2024.

Scripps Research scientists help T cells more effectively kill solid tumors cells in vitro and in mice by tweaking an existing cancer immunotherapy.

Two-mode reactions inspired by human detox enzymes offer powerful new tools for drug discovery and optimization

Scientists transform simple linear amines into saturated heterocycles—ring-shaped structures critical for drug development.

Blocking long phosphate molecules could eventually help treat chronic infections in which slow-growing bacteria evade typical antibiotics.

A new study from Scripps Research and Calibr-Skaggs scientists provides pharmacological proof of concept for an upcoming phase 1 clinical trial.

A Scripps Research team uncovers a cost-effective method for producing quaternary carbon molecules, which are critical for drug development.

Scripps Research chemical biologists design an early “proof-of-concept” vaccine that could lead to the first effective treatment of xylazine overdose in people.

Scripps Research scientists create near-atomic-level structural models of enzymes associated with autoimmune and inflammatory diseases, including lupus and Alzheimer’s.

A Scripps Research team found that a new therapeutic that targets the kappa opioid receptor in the brain may reduce alcohol dependence.

A Scripps Research team shows that suppressing the activity of certain stress neurons may decrease alcohol use—but not anxiety—in comorbid cases of post-traumatic stress disorder and alcohol use disorder.

Customized-design approach could streamline the design of novel proteins targeting the hard-to-access cell membrane region.

New Scripps Research trial aims to validate the use of wearables in guiding participants to effectively monitor mental, physical and emotional exertion—a strategy called pacing.

Christopher Parker and Giordano Lippi are unraveling the metabolic and protein mechanisms, respectively, that go awry in aging and disease—including Alzheimer’s.